Kornimate/medical-research-clean huggingface dataset:
the efficacy of giomer versus sodium fluoride in the treatment of hypersensitivity

Conditions: Tooth Hypersensitivity

Summary: to solve the problem of hypersensitivity, i will use two different materials ( giomer versus sodium fluoride) and compare between their effects in reliving the symptoms

the dentin hypersensitivity is characterized by short, sharp pain which can be detected by several methods. the problem is very annoying for the patients and making them seek for effective rapid treatment. it can affect several teeth in one area of the mouth or only one specific tooth. careful diagnosis of such condition necessitates precise differentiation of its signs and symptoms from the other causes of tooth sensitivity which may be resulted from dental caries, micro leakage, cracked tooth or fractured restoration. there are two well-known ways to reduce the discomfort of the hypersensitivity either by blocking the exposed dentinal tubules by occluding materials or use some depolarizing agents that reducing the excitability of the intra dental nerves.most of the desensitizing agents reduces the dentin hypersensitivity by its own way and each one has different long lasting effect. but there are some drawbacks that appeared with their use. fluoride based agents were appeared in 90's but it was clarified that their high concentration irritated the odontoblasts. furthermore, the oxalates and potassium nitrate were introduced to treat the hypersensitivity effectively but their effects did not persist for a long period of time. sodium fluoride varnish is one from the most commonly used desensitizing agent and its efficacy was approved in many studies. the giomer varnish containing surface pre-reactive glass particles (s-prg) is a light-cured protective varnish and it was introduced to promote prolonged protection for the hypersensitive dentin.

Eligibility criteria:
inclusion criteria: * patients aged from 18 to 40 years. * no gender restriction. * patients should have pain score in the visual analog scale two or more. * patients must have at least one sensitive tooth in one of four quadrants. exclusion criteria: * patients with active carious lesions. * needing restorative treatment. * receiving periodontal treatment. * taking desensitizing treatment in the last 6 months. * taking anti-inflammatory drugs. * pregnant patients. * smokers.
short term genetic effects of chemotherapy on male germ cells

Conditions: Cancer

Summary: this study will determine the short-term effects of chemotherapy on sperm dna.the study involves the collection of semen sample through ejaculation prior to initiation of chemotherapy and up to three time points after initiation of chemotherapy.

while medical advances in the area of cancer treatment have successfully improved the overall detection and treatment of many cancers affecting men and women alike, these very treatment modalities can adversely affect their reproductive capacity. certain types of chemotherapy, such as alkylating agents, are notorious for placing patients at high risk for infertility. for men, the best recommendation for patients undergoing such therapy is to cryopreserve semen prior to initiation of chemotherapy. unfortunately, this may not always occur. some patients have been noted to present to discuss fertility preservation options after completing their first cycle of chemotherapy. in this situation, they will most likely still have sperm which was produced prior to chemotherapy that can be collected even if the stem cells producing the sperm have been damaged or destroyed. however, there are no national guidelines addressing this particular situation. typically, physicians may advise men to avoid conception anywhere from three months to two years after the final dose of chemotherapy to ensure all exposed germ cells have passed through and only newly formed germ cells remain. it is crucial to further assess the effects of chemotherapeutic agents on male germ cells in the short window of time between exposure and potential sterility. if a safe time frame could be determined to collect sperm after a single dose of chemotherapy, then these men could be given a second chance to retain their fertility potential.

Eligibility criteria:
inclusion criteria: * be scheduled to undergo treatment with chemotherapeutic agents for a medical indication * be able to produce semen samples prior to chemotherapy and one week after first round of chemotherapy exclusion criteria: * men who have previously been treated with chemotherapeutic agents. * men with significant oligospermia or azospermia.

Keywords: male infertility germ cells chemotherapy sperm
a pilot treatment study of insulin-like growth factor-1 (igf-1) in autism spectrum disorder

Conditions: Autism Spectrum Disorder

Summary: the proposed project will pilot the use of igf-1 as a novel treatment for core symptoms of autism. we will use a double-blind, placebo-controlled crossover trial design in five children with autism to evaluate the impact of igf-1 treatment on autism-specific impairments in socialization, language, and repetitive behaviors. we expect to provide evidence for the safety and feasibility of igf-1 in ameliorating social withdrawal in children with autistic disorder. further, we expect to demonstrate that igf-1 is associated with improvement on secondary outcomes of social impairment, language delay, and repetitive behavior, as well as on functional outcomes of global severity.

igf-1 is an fda approved, commercially available compound that crosses the blood-brain barrier and has beneficial effects on synaptic development by promoting neuronal cell survival, synaptic maturation, and synaptic plasticity. igf-1 is effective in reversing mouse and neuronal models of rett syndrome and phelan mcdermid syndrome, both single gene causes of asd and may therefore be effective in treating autism spectrum disorders (asd) more broadly.

Eligibility criteria:
inclusion criteria: * meet dsm-5 criteria for autism spectrum disorder confirmed by the autism diagnostic interview-revised (adi-r) and the autism diagnostic observation schedule- generic (ados-g) * children between the ages of 5-12 years of age * language delay (lack of fluent phrase speech) reflected by use of ados module 1 or 2 * must be on stable medication regimens for at least three months prior to enrollment, assuming the concomitant medication is safe for use with igf-1 exclusion criteria: * closed epiphyses * active or suspected neoplasia * intracranial hypertension * hepatic insufficiency * renal insufficiency * cardiomegaly/valvulopathy * history of allergy to igf-1 * patients with comorbid conditions deemed too medically compromised to tolerate the risk of experimental treatment with igf-1

Keywords: autism spectrum disorder igf-1
inhaled corticosteroid use to prevent acute chest syndrome recurrence in children between 1 and 4 with sickle cell disease: a feasibility trial

Conditions: Sickle Cell Disease; Asthma; Acute Chest Syndrome

Summary: acute and chronic pulmonary complications with concomitant inflammatory response are a leading cause of morbidity and mortality in children with sickle cell disease (scd). acute chest syndrome (acs), defined broadly as an increase in respiratory effort, fever and new radiodensity on chest x-ray, is a major cause of death in children and adults with scd. there is a high rate of acs in children between 1 and 4 years of age that is associated with an asthma diagnosis, and children with acs events before 4 years of age have a 50% rate of being hospitalized for either acs or pain within 1 year of admission. for children with scd that develop acs, the investigators propose that the use of budesonide inhalation suspension (bis) will attenuate pulmonary inflammation after an acs episode and will decrease future vaso-occlusive pain and acs episodes. through a single-arm prospective feasibility trial and in preparation for a limited-institution randomized trial, the investigators plan to test the following primary hypothesis for a phase iii definitive trial: in children with scd admitted to the hospital for an acs episode between 1 and 4 years of age, low dose bis for 6 months will result in a 50% reduction in the recurrent incidence rate of acs or pain requiring hospitalization. through this trial, the investigators will determine the acceptability of and adherence to bis in the study population. the investigators will track respiratory symptoms in cases versus controls over 6 months. finally, the investigators will explore the impact of bis on biological correlates (svcam-1).


Eligibility criteria:
inclusion criteria: * 1) confirmed diagnosis of sickle cell disease (scd) * 2) age between 1 and 4 years (must have reached 1st but not yet 4th birthday) * 3) a prior diagnosis of acs, defined as acute respiratory illness with a new radiodensity on cxr, and one of the following: fever (temperature \> 38.50c), decrease in oxygen saturation more than 3% from baseline, or increase in respiratory rate above baseline exclusion criteria: * 1) patients already taking inhaled corticosteroids * 2) those receiving blood transfusions for elevated tcd or strokes * 3) presents over 2 weeks after discharge from hospital following initial acs episode. participants may be on hydroxyurea and participate in this trial.

Keywords: sickle cell disease budesonide inhalation suspension acute chest syndrome
observation on the curative effect of acupuncture at sensitized points on gallbladder meridian in the treatment of neck type cervical spondylopathy

Conditions: Cervical Spondylopathy

Summary: to investigate the changes of acupoint sensitization characteristics of patients with neck type cervical spondylopathy through gallbladder meridian observe the curative effect of acupuncture intervention and optimize the clinical diagnosis and treatment plan of acupuncture treatment of neck type cervical spondylopathy


Eligibility criteria:
inclusion criteria: * meeting the diagnostic criteria of neck type cervical spondylopathy. * age 18 to 65 years old gender is not limited. * clear awareness good compliance willing to cooperate with the study and accept the experimental arrangement. * physical examination may or may not be accompanied by positive signs of the musculoskeletal system (including limited motor function local tender points etc.). * the visual analogue scale (vas) score was more than 3 points and less than 7 points (ranging from 0 to 10 points). * informed consent and sign informed consent. exclusion criteria: * it does not meet the diagnostic criteria and inclusion criteria of cervical spondylosis. * under 18 years of age or over 65 years of age; * 2 weeks before the start of the experiment the relevant treatment of the disease or the use of relevant therapeutic drugs; * patients with other types of cervical spondylosis (cervical radiculopathy vertebral artery type cervical spondylosis cervical myelopathy sympathetic cervical spondylosis) or with other serious organic diseases and patients with neck and shoulder pain caused by non-neck diseases; * patients with cardiovascular and cerebrovascular liver kidney digestive system blood system and other serious life-threatening primary diseases or suffering from hemorrhagic diseases or skin diseases or pregnant or lactating women or have a history of cardiac pacemaker implantation; * previous history of neck surgery or neck fracture; * persons with confusion mental disorder or cognitive impairment; * the skin at the test site has scars redness swelling heat and pain that affect the test result.
the effect of reflexology on sleep quality and fatigue in postmenopausal women

Conditions: Healthy; Nursing Caries

Summary: introduction: this study was conducted to determine the effect of reflexology on sleep quality and fatigue in postmenopausal women.

this study was conducted in batıkent family health center of the ministry of health between may-december 2018. the sample of the study consisted of 72 postmenopausal women. the data were collected by using the introductory information form, pittsburgh sleep quality index and fatigue severity scale. a total of 12 reflexology sessions were applied to the postmenopausal women by the researcher twice a week. no intervention was applied to the postmenopausal women in the control group.

Eligibility criteria:
inclusion criteria: * able to communicate, * aged 50 to 65, exclusion criteria: * taking hormone replacement therapy, * chronic diseases (such as diabetes, hypertension, and so on), * psychiatric disease, * diagnosed with a sleep disorder attributed to other cause * menstruation for more than one year * history of alcohol or drug addiction

Keywords: nurse postmenopausal women sleep reflexology fatigue
mandarin (s6371)

Conditions: Inoperable Hepatocellular Carcinoma

Summary: to evaluate the efficacy and safety of theraspheretm yttrium \[90y\] glass microsphere in the chinese patients with inoperable hepatocellular carcinoma.


Eligibility criteria:
inclusion criteria: * ≥18 and ≤80 age and provided study consent * patients diagnosed with hcc and clinically evaluated as inoperable (as per local practice) or who refuse operation (ablation, hepatectomy and liver transplantation) * at least one well defined hcc tumor measurable by mrecist in contrast-enhanced mri * china liver cancer staging (cnlc) stage ib\~iib * child-pugh ≤ b7 * eastern cooperative oncology group (ecog) performance status ≤ 1 * tumor burden ≤50% of the total liver volume exclusion criteria: * presence of extra-hepatic metastases or additional malignancies aside from hcc * patients with hepatic artery malformation and unable to intubate hepatic artery * patients who are allergic to contrast agents or have renal insufficiency (serum creatinine\>2mg/ml or creatinine clearance\<30ml/min) and are not suitable for injection of contrast agents * severe pulmonary insufficiency (fev1/fvc\<50% or fev1/predicting value\<50% or mvv\<50l/min) * ast and alt \>5 times upper limit of normal * clinical manifestations of decompensated cirrhosis (grade2/3 of ascites, gastrointestinal bleeding, hepatic encephalopathy, etc. according to easl clinical practice guidelines) * hcc invading biliary tract or causing biliary obstruction * uncorrectable coagulation dysfunction and severe hemogram abnormality \[prothrombin time (pt)\>6 seconds above control or pt-international normalized ratio (inr)\>2.5, wbc\<3.0x109/l, plt\<50x109/l\] * infiltrative hcc tumor type * bilobar hcc disease * any presence of portal vein or hepatic veins or artery invasion * occlusion of portal vein completely with less collateral vessels * transjugular intrahepatic portosystemic shunt (tips) or hepatic arterioportal fistula * patients during pregnancy or lactation * prior interventional therapy via hepatic artery or radiotherapy treatment for hcc * tc-99m macroaggregated albumin (maa) hepatic arterial perfusion scintigraphy shows any deposition to the gastrointestinal tract that may not be corrected by angiographic techniques * radiation pneumonitis has been seen in patients receiving doses to the lungs greater than 30 gy in a single treatment or greater than 50gy in multiple treatment * the absorbed dose of lung may exceed 30gy in preoperative evaluation * receive any investigational therapy or anti-tumor therapy within 30 days prior to study enrollment * any other reason in which the investigator believes that the patient is unsuitable to participate in this trial
second extension study to evaluate safety and tolerability of influenza vaccines in adults and elderly, and to evaluate immunogenicity and concomitant vaccination with pneumococcal vaccine in a subgroup

Conditions: Influenza

Summary: the study primarily aims to evaluate immunogenicity and safety of influenza vaccines (cell culture derived seasonal trivalent influenza vaccine (ctiv) or influenza virus vaccine (egg-derived seasonal trivalent, thiomersal free; etiv_a)) when administered alone and when administered concomitantly with pneumococcal polysaccharide vaccine (pv) in elderly subjects. the study also aimed to evaluate safety and immunogenicity (subset) of annual vaccination with either ctiv or etiv_a in adults and elderly subjects.


Eligibility criteria:
inclusion criteria: * participation in the v58p4 study * mentally competent to understand the nature, the scope and the consequences of the study * able and willing to give written informed consent prior to study entry * available for all the visits scheduled in the study exclusion criteria: * receipt of another investigational agent within 90 days prior to, or before completion of the safety follow-up period in another study, whichever is longer, prior to visit 7 and unwilling to refuse participation in another clinical study through the end of the present study * history of any anaphylaxis, serious vaccine reactions, or allergy to any of the vaccine components * any acute respiratory disease or infections requiring systemic antibiotic or antiviral therapy (chronic antibiotic therapy for urinary tract prophylaxis was acceptable) or experienced fever (i.e., axillary temperature ≥ 38°c) within the 5 days prior to visit 7 * pregnant/breast feeding women, or women of childbearing potential who refuse to use a reliable contraceptive method during the three weeks after vaccination
parisk: correlation of imaging techniques with histology

Conditions: Stroke; Plaque, Atherosclerotic

Summary: the possibility to identify the risk of rupture of a carotid plaque will have tremendous impact in clinical decision making. a vulnerable plaque is considered to have a large lipid rich necrotic core (lrnc), a thin fibrous cap, the presence of inflammatory cells, intraplaque haemorrhage and/or neovascularisation (vasa vasorum). the investigators aim to validate imaging of plaque vulnerability with histology. previous studies have evaluated the use of imaging to assess carotid plaque vulnerability, mostly showing a good correlation between imaging and histology and/or clinical characteristics. however, they have focused on single modalities, (magnetic resonance imaging \[mri\], multidetector-row computed tomography (mdct), ultrasonography (us) or transcranial doppler (tcd), and have used relatively small cohorts the primary goal of this study is to investigate whether there is a correlation between neovascularisation in the carotid atherosclerotic plaque as observed with 3.0 tesla dynamic contrast-enhanced mri and histology. moreover, the investigators aim to investigate the correlation between the volume of the lrnc as determined by dual-energy ct and histology. secondly, the investigators will investigate the correlation between the volume of the lrnc, the fibrous cap status and the volume of the calcifications determined by mri versus histology, the correlation between number of microembolisms and fibrous cap status and the correlation between the deformation pattern seen with ultrasound and the volume of the lrnc. the imaging parameters showing good correlation with plaque vulnerability characteristics can be used for further analysis in assessing the vulnerable plaque


Eligibility criteria:
inclusion criteria: * patients with a carotid artery stenosis, who are scheduled for carotid endarterectomy * age 18 years or older (no maximum age) * informed consent by signing informed consent form regarding this study * inclusion criteria for carotid endarterectomy 1. symptomatic carotid artery stenosis 70-99% within 3 months of neurological symptoms 2. symptomatic carotid artery stenosis 50-99% in man within 2 weeks of neurological symptoms 3. asymptomatic carotid artery stenosis 70-99% with contralateral occlusion exclusion criteria: * severe co-morbidity, dementia or pregnancy * standard contra-indications for mri (ferromagnetic implants like pacemakers or other electronic implants, metallic eye fragments, vascular clips, claustrophobia, etc.) * patients who have a documented allergy to mri or ct contrast media * patients with a renal clearance \<30 ml/min are not eligible to undergo contrast-enhanced mri * patients with a renal clearance \<60 ml/min are not eligible to undergo ct * surgery planned within 4 days of inclusion

Keywords: endarterectomy, carotid carotid arteries
drug drug interaction study evaluating the effect of fluvoxamine or fluconazole on pk and safety of pf-04965842.

Conditions: Dermatitis, Atopic

Summary: a phase 1, open label, parallel-cohort, randomized, fixed sequence study to evaluate the pharmacokinetic drug drug interaction between pf-04965842 and fkuvoxamine (cohort 1) or fluconazole (cohort 2) in healthy subjects.

a phase 1 study to evaluate the effect of fluvoxamine (a strong cyp2c19 and moderate cyp3a inhibitor) or fluconazole (a strong cyp2c19, moderate cyp2c9 and cyp3a inhibitor) on the pharmacokinetics, safety and tolerability of pf-04965842 in healthy subjects. this study will be a phase 1, open label, randomized, fixed-sequence, parallel-cohort study drug-drug interaction study. the study includes 2 periods: in period 1: all subjects will receive one single oral dose of 100 mg pf 04965842 tablet. (treatment a). pk will be evaluated in the first 72 hours post adminstration of pf 04965842. in period 2: * cohort 1: subjects will receive fluvoxamine (immediate release tablet 50 mg) once daily for 9 consecutive days; on day 8, subjects will receive a single oral dose of 100 mg pf 04965842 approximately 3 hours after fluvoxamine administration. (treatment b). pk will be evaluated in the first 72 hours post administration of pf 04965842. * cohort 2: subjects will receive fluconazole capsule(s) once daily for 7 consecutive days (400 mg on day 1 and 200 mg on day 2-7 in period 2); on day 5, subjects will receive a single oral dose of 100 mg pf 04965842 approximately 1 hour after fluconazole administration. (treatment c). pk will be evaluated in the first 72 hours post administration of pf 04965842.

Eligibility criteria:
inclusion criteria: * healthy male or female subjects. * body mass index (bmi) of 17.5 to 30.5 kg/m2 and a total body weight \>50 kg (110 lb). exclusion criteria: * evidence or history of hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurological, or allergic disease. * evidence or history of clinically significant dermatological condition (eg, contact dermatitis or psoriasis) or visible rash present during physical examination. * history of hypersensitivity to or intolerance of fluvoxamine and/or fluconazole. * any condition possibly affecting drug absorption. * a positive urine drug test. * screening supine systolic bp \<90 mm hg or 140 mm hg following at least 5 minutes of supine rest or screening supine diastolic bp \<50 mm hg or 90 mm hg following at least 5 minutes of supine rest. * pregnant female subjects; breastfeeding female subjects; fertile male subjects and female subjects of childbearing potential who are unwilling or unable to use a highly effective method of contraception.

Keywords: atopic dermatitis